ClinicalTrials.gg
Not yet recruitingNCT06929104Updated Apr 16, 2025

Psychological Problems in Post Thyroidectomy Patients

An observational study in Post-Thyroidectomy Hypoparathyroidism, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-16.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
127
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Quality of life (QoL) refers to perceived well-being, and encompasses the evaluation of physical health, and physical, social, and psychological functioning .

The assessment of quality of life (QOL) post-thyroidectomy has gained significant attention in the medical community. Multiple studies have delved into the long-term consequences of thyroidectomy, aiming to evaluate the impact on patients' overall well-being and functional status. By examining numerous aspects, such as the physical, psychological, and social dimensions of QOL, researchers have provided valuable insights into the outcomes of thyroidectomy, hence contributing to improving patient care and enhancing their postoperative experiences.

Read the detailed description

Regarding the psychological dimension of QOL, several studies have emphasized patients' emotional well-being post-thyroidectomy. Findings have demonstrated that, while many individuals experience temporary emotional disturbances related to the surgery, long-term psychological outcomes generally improve over time. In fact, the majority of patients report higher levels of self-esteem and body image post-thyroidectomy, as the removal of a diseased or abnormal thyroid gland can alleviate anxiety and distress associated with the underlying condition. However, additional research is needed to explore the specific factors contributing to these positive psychological outcomes and to identify potential interventions for those experiencing psychological distress following thyroidectomy .

Thyroidectomy is the treatment of choice in thyroid cancer patients, and the prevalence of thyroid cancer has shown a gradual increase over the past two decades. Thyroid surgery is also indicated in certain forms of benign thyroid disorder, such as nontoxic goiter and Graves' disease. Although thyroidectomy is a universal operation, few studies to date have investigated the impact of thyroidectomy on QOL .

02

Conditions studied

  • Post-Thyroidectomy Hypoparathyroidism

Browse trials for

03

In context

Hypoparathyroidism

128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.

This study's planned enrollment of 127 is below the median of 147 across 48 observational studies indexed under Hypoparathyroidism.

Browse Hypoparathyroidism studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients undergo thyroidectomy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1-Gender: both males and females 2- Post thyroidectomy patients: patients who will be planned to undergo different types of thyroidectomy for conditions such as thyroid cancer, benign thyroid disease (goiter), or hyperthyroidism (e.g., Graves' disease) and admitted as inpatients.

    3- Age Range: participants within certain age range (e.g., 18-75 years). 4-Consent: Ability to provide to participate in the study. 5-Stable Medical Condition:

Exclusion criteria

Exclusion Criteria:

  1. Patients who were previously diagnosed with any psychiatric diseases.
  2. Medications: Use of medications that could affect outcome of the study e.g., antidepressants, and benzodiazepines
  3. Pregnancy: Current pregnancy or breastfeeding.
  4. Age: less than 18 years or more than 75 years old.
  5. patients with any organ failure e.g (heart failure, end-stage renal disease requiring dialysis and liver failure) and cancers other than thyroid cancer.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
127 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients undergo thyroidectomy

    Other: No intervention

Interventions

  • OtherNo intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. To assess the prevalence of psychological problems e.g., depression, anxiety and fatigue in patients with post thyroidectomy surgery in Assiut University hospitals.

    Time frame: One year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06929104
Lead sponsor
Assiut University
Responsible party
Gehad M Galal (Gehad M Galal, Assiut University) — Principal investigator
First posted
Apr 16, 2025
Start date
May 1, 2025 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Apr 16, 2025

Study contacts

Gehad Galal, Master degree
Contact
gehad.m.galal20@gmail.com
01007296201

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion